Evidence map›Paper›PMID 41279098›Full record

ArticlebioRxiv : the preprint server for biology2025

Photoaffinity labeling of protein targets in a complex metazoan: proof-of-concept using a probe for

Bobby Lucero, Thibault Alle, Marianna Bufano, Yuemang Yao, Kurt R Brunden, Andrea Brancale, Carlo Ballatore, Karol R Francisco, Conor R Caffrey

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bobby LuceroDepartment of Chemistry & Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Thibault AlleCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9255 Pharmacy Lane, MC0657, La Jolla, CA 92093, USA.
Marianna BufanoDepartment of Organic Chemistry, University of Chemistry and Technology, Technická 5, Prague 6 16628, Czech Republic.
Yuemang YaoCenter for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104, USA.
Kurt R BrundenCenter for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104, USA.
Andrea BrancaleDepartment of Organic Chemistry, University of Chemistry and Technology, Technická 5, Prague 6 16628, Czech Republic.
Carlo BallatoreDepartment of Chemistry & Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Karol R FranciscoCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9255 Pharmacy Lane, MC0657, La Jolla, CA 92093, USA.
Conor R CaffreyCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9255 Pharmacy Lane, MC0657, La Jolla, CA 92093, USA.

Funding

RESEARCH IN INFECTIOUS DISEASEST32AI007036 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 1985 to 2025
$9.2M
Development of thiophen-2-yl-phenylpyrimidines for treatment of schistosomiasisR21AI156554 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BALLATORE, CARLO, CAFFREY, CONOR · 2021 to 2022
$435k
NIAID NIH HHS R21 AI156554NIAID NIH HHS T32 AI007036
6 · The paper itself

Abstract

Treatment of schistosomiasis, a prevalent neglected tropical disease, relies precariously on a single drug. The discovery and development of alternative anti-schistosomal small molecules most often relies on phenotypic (whole-organism) screening, whereas target- or "protein-first"-based discovery options are hampered by a paucity of genetic interrogation strategies and a complex biology. Here, we demonstrate the application of photoaffinity labeling (PAL) as a chemical biology strategy to probe protein target-ligand interactions in the schistosome. Using a triazolopyrimidine (TPD) probe that binds tubulin, we established a PAL workflow with living

Identifiers

PMID41279098
PMCPMC12632543

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.